In this session, you'll learn:

• How to work up an Acute Neuropathy for the Boards
• How to work up and diagnose a Polyneuropathy for the boards
• How to recognize and diagnose a mononeuropathy multiplex for the boards

Scott L. Spradlin, DO, FACOI, VP Strategic Clinical Operations and Policy Delivery, Aetna

In this session, you'll learn how to:

• Diagnose selected genetic conditions.
• Anticipate selected conditions based upon patients’ genetics disorders.
• Correlate genetic inheritance with selected conditions.

Robert T. Hasty, DO, FACOI, FACP, Dean & Chief Academic Officer, Orlando College of Osteopathic Medicine (Proposed)

In this session, you'll learn:

• Overview of Headaches and Treatment for the Boards
• Review of Parkinson's, Seizures, and Motor Disorders for the Boards
• Overview of Myopathies and Treatments for the Boards

Scott L. Spradlin, DO, FACOI, VP Strategic Clinical Operations and Policy Delivery, Aetna

In this session, you'll learn how to:

• Educate patients on appropriate diets tailored to their comorbid conditions.
• Prevent exacerbations of selected conditions by prescribing appropriate diets.
• Improve patients’ health outcomes by choosing selected diets.

Robert T. Hasty, DO, FACOI, FACP, Dean & Chief Academic Officer, Orlando College of Osteopathic Medicine (Proposed)

In this session, you’ll learn how to:
-    Review rheumatologic conditions with cutaneous manifestation.
-    Identify common presentations of psoriasis and its systemic comorbidities.
-    To review current cutaneous finding of syphilis and COVID-19. 

Molly Menser, DO, Clinical Preceptor, Dermatology, Kansas City University College of Osteopathic Medicine

In this session, you'll learn about:

• General Overview of Types of Strokes for the Boards
• General Overview of Multiple Sclerosis for the Boards
• Clinical Stratification for Neurological Board Cases

Scott L. Spradlin, DO, FACOI, VP Strategic Clinical Operations and Policy Delivery, Aetna

In this session, you’ll learn how to:
-    Understand the concepts pertaining to and the pathophysiology behind prostate enlargement and declining bladder function.
-    Understand the management algorithm for overactive bladder and urinary incontinence in the female patient. 
-    Improve your interpretation of the serum prostate specific antigen (PSA) test. 

Joel Abbott, DO, FACOS, Director of Endourology & Kidney Stone Disease, Pacific West Urology